Fortekor Flavour

1 x 28 pc

Tablet

Active substance

Benazepril (Benazepril hydrochloride) : 5 mg

ATC code

QC09AA07 Benazepril

QC09AA ACE inhibitors, plain

QC09A ACE inhibitors, plain

QC09 Agents acting on the renin-angiotensin system

QC Cardiovascular system

Species

Dogs and cats.

Indications

Dogs:

Treatment of congestive heart failure.

Cats:

Reduction of proteinuria associated with chronic kidney disease.

Dose to be administered and administration route

Oral use.

The veterinary medicinal product should be given once daily, with or without food. The duration of treatment is unlimited.

This product is flavoured and is taken voluntarily by most dogs and cats.

Dogs:

This veterinary medicinal product should be administered orally at a minimum dose of 0.25 mg (range 0.25-0.5) benazepril hydrochloride/kg body weight once daily, according to the following table:

Weight of dog (kg)	5 mg tablet strength
Weight of dog (kg)	Standard dose	Double dose
>5 - 10	0.5 tablet	1 tablet
>10 - 20	1 tablet	2 tablets

The dose may be doubled, still administered once daily, to a minimum dose of 0.5 mg/kg (range 0.5-1.0), if judged clinically necessary and advised by the veterinary surgeon.

Cats:

This veterinary medicinal product should be administered at a minimum dose of 0.5 mg (range 0.5-1.0) benazepril hydrochloride/kg body weight once daily according to the following table:

Weight of cat (kg)	5 mg tablet strength
2.5 – 5	0.5 tablet
>5 – 10	1 tablet

Adverse reactions

Dogs;

Rare

(1 to 10 animals / 10,000 animals treated):

Diarrhoea, Vomiting, Anorexia, Fatigue

Very rare

(<1 animal / 10,000 animals treated, including isolated reports):

Elevated creatinine^¹

Incoordination,

Cats:

Rare

(1 to 10 animals / 10,000 animals treated):

Diarrhoea Emesis,

Anorexia, Dehydration, Lethargy

Very rare

(<1 animal / 10,000 animals treated, including isolated reports):

Elevated creatinine¹

Increased appetite, Weight gain

¹In cats with chronic kidney disease, the product may increase plasma creatinine concentrations at the start of therapy. A moderate increase in plasma creatinine concentrations following administration of ACE inhibitors is compatible with the reduction in glomerular hypertension induced by these agents, and is therefore not necessarily a reason to stop therapy in the absence of other signs.

Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or its local representative or the national competent authority via the national reporting system. See also the last section of the package leaflet for respective contact details.